|
Published: April 2017
|
Report Code: LS11014 |
Available Format: 
|
Pages: 94
|
|
Category : Pharmaceuticals
|
|||
Ewing sarcoma is a condition in which formation of cancer or tumor takes place in the bones and soft tissues. It is the second most common type of primary sarcoma found in young adults and children. Ewing sarcoma occurs in ribs, long bones, spine (vertebral column) and pelvis. The prevalence of Ewing sarcoma has increased in the past few years, but the exact cause of the disease is still unknown; some of the risk factors that increase the probability of occurrence of Ewing sarcoma include genetic changes (translocation between the chromosomes), age, gender (Ewing sarcoma is more common in males as compared to females), ethnicity (Ewing sarcoma is more commonly found in white people as compared to black people in the U.S.). According to the American Cancer Society, it is estimated that around 30 children in the U.S. get affected with Ewing sarcoma every year. Ewing sarcoma is a very severe form of cancer that occurs among the children aged between 10 to15 years of age. The disease can be easily diagnosed through magnetic resonance imaging scan, CT scan, positron emission tomography scan and biopsy. Some of the symptoms associated with Ewing sarcoma includes pain as well as swelling in chest, back, legs, pelvis and arms, fever, bone fracture, weight loss, loss of appetite, fatigue and malaise.
Around 44.0% of the active pipeline drug candidates of Ewing sarcoma are small molecules, while 19.0% are antibody drug conjugate. Approximately, 18.0% of the drug candidates are monoclonal antibodies. The percentage share of others molecule is 19%, which includes fusion protein, vitamin, bispecific antibody and recombinant protein.
GLOBAL EWING SARCOMA THERAPEUTICS PIPELINE SPLIT, BY MOLECULE TYPE (2017)
The major players including Celgene Corporation, Pfizer Inc., Novartis Pharmaceuticals, Merrimack Pharmaceuticals, Celldex Therapeutics, Oncternal Therapeutics, Astellas Pharma Inc., Amgen Inc., and Nanovalent Pharmaceuticals are involved in the development of Ewing sarcoma drug candidates. Celgene Corporation and Pfizer Inc. have their drug candidates in the Phase I stage of development, respectively. Nanovalent Pharmaceuticals is the process of developing three pre-clinical drug candidates for Ewing sarcoma. The drug candidates of Oncofusion therapeutics such as ERG-inhibitor, are in pre-clinical stage. OMTX703, that is being developed by Oncomatryx Biopharma, is present in the discovery stage. Ganitumab, the drug candidate of Amgen Inc., is in phase III stage of development.
Some of the key players developing Ewing sarcoma therapeutics include Pfizer Inc., Merrimack Pharmaceuticals, Celldex therapeutics, Celgene Corporation, Oncternal therapeutics, Astellas Pharma, Inc, Nanovalent pharmaceutical, Amgen, Inc, and Novartis AG.
P&S Market Research offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes:
Place An Order
